Theriva Biologics (TOVX) Files 8-K: Office Location Update

Ticker: TOVX · Form: 8-K · Filed: Sep 23, 2024 · CIK: 894158

Theriva Biologics, Inc. 8-K Filing Summary
FieldDetail
CompanyTheriva Biologics, Inc. (TOVX)
Form Type8-K
Filed DateSep 23, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: corporate-info, address-change

Related Tickers: TOVX

TL;DR

TOVX updated its HQ address in Rockville, MD. Nothing else new.

AI Summary

On September 23, 2024, Theriva Biologics, Inc. (TOVX) filed an 8-K report. The filing indicates the company's principal executive offices are located at 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850. Theriva Biologics, Inc. is incorporated in Nevada and its common stock trades on the NYSE American under the ticker TOVX.

Why It Matters

This filing provides updated contact and location information for Theriva Biologics, Inc., which is important for investors and stakeholders to ensure they have the correct address for official correspondence and potential site visits.

Risk Assessment

Risk Level: low — This filing is a routine update of corporate information and does not contain any material financial or operational news that would significantly impact the company's risk profile.

Key Players & Entities

  • Theriva Biologics, Inc. (company) — Registrant
  • 9605 Medical Center Drive , Suite 270 (location) — Principal executive offices address
  • Rockville, Maryland 20850 (location) — Principal executive offices city and zip code
  • Nevada (jurisdiction) — State of incorporation
  • TOVX (ticker) — Trading symbol for common stock
  • NYSE American (exchange) — Exchange where common stock is registered

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report current information about Theriva Biologics, Inc., specifically updating its principal executive offices address.

When was the earliest event reported in this filing?

The earliest event reported in this filing is dated September 23, 2024.

In which state is Theriva Biologics, Inc. incorporated?

Theriva Biologics, Inc. is incorporated in Nevada.

On which stock exchange does Theriva Biologics, Inc. trade?

Theriva Biologics, Inc. common stock trades on the NYSE American.

What is the new address for Theriva Biologics, Inc.'s principal executive offices?

The new address for Theriva Biologics, Inc.'s principal executive offices is 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850.

Filing Stats: 1,009 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-09-23 08:10:25

Key Financial Figures

  • $0.001 — h registered Common stock, par value $0.001 per share TOVX NYSE American Indica

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Theriva Biologics, Inc. (the "Company") will be making several presentations to investors over the next several weeks. In connection with the presentations, the Company intends to discuss the Company presentation, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and in the Company presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The Company's Company presentation furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

01. Other Events

Item 8.01. Other Events. On September 23, 2024, the Company issued a press release announcing that it has achieved its target patient enrollment of 92 evaluable patients in the VIRAGE Phase 2b clinical trial evaluating the Company's lead product candidate VCN-01 plus standard-of-care ("SoC") chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC"). VCN-01 is a systemically-administered, tumor selective, stroma-degrading oncolytic adenovirus that has been granted Orphan Drug Designation and Fast Track Designation by the U.S. Food and Drug Administration ("FDA") for the treatment of PDAC. Patients in the VCN-01 treatment arm of the VIRAGE trial are treated with two separate IV VCN-01 doses (1x10 13 vp/patient) administered approximately 3 months apart: the first VCN-01 dose is administered 7-days prior to initiation of the 1st gemcitabine/nab-paclitaxel SoC chemotherapy cycle; the second VCN-01 dose is administered 7-days prior to initiation of the 4th gemcitabine/nab-paclitaxel SoC chemotherapy cycle. The VCN-01 dose used in the VIRAGE trial was determined in a previously reported Phase 1 dose-escalation study where patients administered a single dose of VCN-01 (1x10 13 vp/patient) 7-days prior to initiation of gemcitabine/nab-paclitaxel SoC chemotherapy cycles (n=6) showed an overall response rate of 83%, with a median progression free survival of 6.3 months and median overall of 20.8 months. A total of 26 patients were administered different doses of VCN-01 in the Phase 1 study, and the most common treatment-related adverse events were dose-dependent and reversible pyrexia, flu-like symptoms, and increases in liver transaminases. At the time of this filing, a total of 142 patients have been administered at least one dose of VCN-01 across all indications. A copy of the press release is attached as Exhibit 99.2 to this Report on Form 8-K, which is furnished as Exhibit 99.2 to this Cur

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Presentation of Theriva Biologics, Inc., dated September 2024 99.2 Press Release issued by Theriva Biologics, Inc., dated September 23, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 23, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.